Bret Michaels tapped for Stop Diabetes campaign
ALEXANDRIA, Va. Rock star and winner of NBC’s “Celebrity Apprentice,” Bret Michaels, has joined the American Diabetes Association’s Stop Diabetes awareness campaign.
Michaels, lead singer of the band Poison, was diagnosed with Type 1 diabetes — also referred to as juvenile diabetes — when he was 6 years old. Michaels will be featured in a public service announcement campaign that he helped produce for the association, which will celebrate American Diabetes Month in November. Prior to becoming the face of the Stop Diabetes campaign, Michaels raised more than $300,000 for the association while on “Celebrity Apprentice,” and continues to support its efforts by working with association volunteers and staff throughout his 2010 tour.
“It is an honor to once again be working with the American Diabetes Association,” Michaels said. “As someone with Type 1 diabetes, I know how difficult it can be to live with this disease and how important it is to raise awareness so that we can eventually put a stop to diabetes. I hope everyone will join me in the movement to Stop Diabetes this November.”
Nearly 24 million children and adults in the United States have diabetes. Diabetes contributes to the deaths of more than 230,000 Americans each year.
FDA approves Par and Tris Pharma’s generic Tussionex
WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a generic treatment for cough and upper respiratory symptoms resulting from colds and allergies made by Par Pharmaceutical and Tris Pharma, Par said Tuesday.
The FDA approved hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension. The drug is a generic version of UCB’s Tussionex, which has annual sales of around $226 million, according to IMS Health.
“The introduction of this first-to-market generic product will improve patient access to a much-needed therapy,” Par EVP and president Paul Campanelli said. “Our partner, Tris Pharma, has once again leveraged its innovative drug-delivery platform to bring this important product market.”
HGS, Novartis halt further development of Zalbin
ROCKVILLE, Md. Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment for hepatitis C following the Food and Drug Administration’s decision to decline its approval, HGS said Tuesday.
HGS said it received a complete response letter from the FDA concerning the drug Zalbin (albinterferon alfa-2b). The FDA delivers a complete response letter to indicate that it has finished reviewing an application, but questions remain that preclude final approval.
HGS did not specify what the issues with the application were, but said it had expected to receive the letter.